Portfolio company Escient Pharmaceuticals was acquired by Incyte.
Escient Pharmaceuticals is a clinical-stage biotechnology company focused on developing GPCR-targeted therapies for neurosensory-inflammatory disorders
Escient Pharmaceuticals is a clinical-stage biotechnology company focused on developing GPCR-targeted therapies for neurosensory-inflammatory disorders. The company is advancing first-in-class small molecule antagonists targeting MRGPRX2 and MRGPRX4 to address serious medical needs.